Abstract

BACKGROUND Dengue virus (DENV) has circulated in Brazil for over 30 years. During this time, one serotype has cyclically replaced the other, until recently, when all four distinct serotypes began to circulate together. Persistent circulation of DENV for long time periods makes sequential infections throughout a person’s life possible. After primary DENV infection, life-long immunity is developed for the infecting serotype. Since DENV and Zika virus (ZIKV) are antigenically similar, the possibility of cross-reactions has attracted attention and has been demonstrated in vitro.OBJECTIVE The aim of this study was to investigate whether immune-sera from DENV and ZIKV infected patients would cross-react in vitro with other Flaviviridae family members. METHODS Cross-reaction of the studied samples with yellow fever virus (YFV), West Nile virus (WNV), Rocio virus (ROCV), Saint Louis virus (SLEV) and Ilheus virus (ILHV) has been investigated by plaque reduction neutralisation test (PRNT) and the antibody-dependent enhancement (ADE) by flow-cytometry.FINDINGS Antibodies against ZIKV and DENV virus cross-reacted with other flaviviruses either neutralising or enhancing the infection. Thus, viral entrance into FcRFcɣRII-expressing cells were influenced by the cross-reactive antibodies. ZIKV or DENV immune sera enhanced cellular infection by WNV, ILHV, ROCV and SLEV. Finally, DENV immune sera presented higher neutralising activity for YFV and SLEV. While ZIKV immune sera neutralised WNV, ILHV and ROCV with high frequencies of positivity. MAIN CONCLUSIONS The co-circulation of those viruses in the same area represents a risk for the development of severe infections if they spread throughout the country. Successive flavivirus infections may have an impact on disease pathogenesis, as well as on the development of safe vaccine strategies.

Highlights

  • Dengue virus (DENV) has circulated in Brazil for over 30 years

  • Enhancement of virus infection in vitro assay – An antibody dependent enhancement (ADE) assay was performed with dengue virus (DENV) and Zika virus (ZIKV) immune sera collected from patients to test the augmentation of infection in FcɣRII-expressing K562 cell lines

  • plaque reduction neutralisation test (PRNT) – PRNT 90 % (PRNT90) assays were performed in BHK-21 cells, as previously described.[12]. Serial dilutions of previously positive DENV, ZIKV and DENV/ZIKV serum (1:10 to 1:5120) were mixed with 100 plaque forming units (PFU) of selected flaviviruses (ZIKV-PE243, YFV17D, YFV-prM/E-WNV, YFV-prM/E-ILHV, YFV-prM/ E-SLEV and YFV-PrM/E-ROCV), incubated for 1 hour at 37oC, added to the cells and incubated at 37oC for an additional hour

Read more

Summary

BACKGROUND

Dengue virus (DENV) has circulated in Brazil for over 30 years. During this time, one serotype has cyclically replaced the other, until recently, when all four distinct serotypes began to circulate together. Persistent circulation of DENV for long time periods makes sequential infections throughout a person’s life possible. After primary DENV infection, life-long immunity is developed for the infecting serotype. Since DENV and Zika virus (ZIKV) are antigenically similar, the possibility of cross-reactions has attracted attention and has been demonstrated in vitro

METHODS
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call